German mRNA pioneer BioNTech will acquire InstaDeep, an artificial intelligence and machine learning specialist, for around £362m ($439m): pledging to incorporate rapidly evolving AI capabilities into its research, drug discovery, manufacturing and deployment...
BigHat Biosciences, a US biotech with a machine learning-guided antibody discovery and development platform, has announced a collaboration with Merck to apply its technology to design candidates for up to three drug discovery programs.
Sanofi and Insilico Medicine have announced a multi-year, multi-target strategic research collaboration: leveraging Insilico’s ‘Pharma.AI’ platform to advance drug development for up to six new targets.
Colossal Biosciences spins out Form Bio, which emerges with funding and a software platform that is designed to be used across drug discovery, cell and gene therapy, manufacturing, and academic research.
iBio is jockeying for position as a leading player in AI-powered drug discovery while also expanding its immuno-oncology pipeline after closing on the acquisition of multiple assets from its partner, RubrYc Therapeutics.
Novo Nordisk and Microsoft have entered a new strategic collaboration to combine Microsoft’s computational services, cloud, and artificial intelligence (AI) with Novo Nordisk’s drug discovery, development, and data science capabilities.
The AI and QC specialists have joined to use AI and QC in order to discover biological pathways relevant to the treatment of triple-negative breast cancer.
Merck (MSD outside the US and Canada) is welcoming applications from early-stage biomedical start-ups for its newly launched Merck Digital Sciences Studio (MDSS): which seeks to support technologies for drug discovery and development.
What are the opportunities, challenges and innovation drivers across healthcare? From its 2022 Global Annual Meeting, the DIA tells us the key issues it's keeping its eyes on.
Pfizer is set to acquire Australia’s ResApp - a company developing a smartphone app to detect COVID-19 and other respiratory diseases based on the user’s cough - for $100m AUD ($74m USD).
Stevenage Bioscience Catalyst (SBC) has launched an accelerator program for biotech start-ups focusing on data-enabled drug discovery, genomics and advanced therapies: aiming to give such companies the skills they need to get potential new drugs and therapies...
AION Labs, a ‘first-of-its-kind’ innovation lab that will create and adopt AI technology to transform the process of drug discovery and development, has officially launched this month.
Engine Biosciences, a Singapore- and Silicon Valley-based company with an artificial intelligence-enabled technology platform that is designed to discover new biology targets and disease-causing links amongst known targets, has generated US$43m in a Series...
A test which uses artificial intelligence (AI) to measure proteins present in some patients with advanced bowel cancer could hold the key to more targeted treatment, according to a study published in Clinical Cancer Research.
BioNTech and InstaDeep are creating a joint AI innovation lab in Europe to develop novel immunotherapies. “We see a significant opportunity at the intersection of AI and immunology by computational design of new precision immunotherapies,” says BioNTech....
GSK signs partnership deal with the University of California to advance genomic research, which sees the creation of a lab and funding for five years of research.
